Lakefront Biotherapeutics (LKFT) Change in Cash (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Change in Cash for 11 consecutive years, with -$24.8 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Cash fell 148.23% year-over-year to -$24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.2 million (down 211.79% YoY) and the FY2025 annual result came in at $32.0 million, up 126.91% from the prior year.
• Change in Cash slipped to -$24.8 million in Q1 2026 per LKFT's latest filing, from $28.2 million in the prior quarter.
• Over the last five years, Change in Cash for LKFT reached as high as $51.4 million in Q1 2025 and fell as low as -$1.1 billion in Q1 2022.
• A 5-year average of -$142.9 million and a median of -$18.6 million in 2024 frame the typical range for Change in Cash.
• The largest YoY upside for Change in Cash was 235.14% in 2025 against a maximum downside of 2236.52% in 2025.
• Year by year, Change in Cash stood at -$186.2 million in 2022, then jumped by 105.1% to $9.5 million in 2023, then retreated by 11.54% to $8.4 million in 2024, then jumped by 235.14% to $28.2 million in 2025, then sank by 187.91% to -$24.8 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$24.8 million, $28.2 million, and -$8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.